( The drug major Merck has launched the f...)First head-to-head trials of once weekly Fosamax and Actonel therapies,Health

The drug major Merck has launched the first two head-to-head clinical trials that compare the efficacy and tolerability of Fosamax (alendronate) once weekly 70mg and Actonel (risedronate) once-weekly 35mg. Fosamax and Actonel, both bisphosphonates indicated for the treatment of osteoporosis in post menopausal women are co-marketed by Aventis and Procter & Gamble through the Alliance for// Better Bone Health. The trial called FACTs(Fosamax Actonel Comparison Trials), is being sponsored by Merck as a US-based study, as well as an international study, each of which will examine approximately 800 post menopausal women with osteoporosis(defined by a bone mineral density (BMD) T-score of <=-2). The participants will be randomized in a one-to-one blinded fashion to either alendronate 70mg once weekly or risedronate 35mg once weekly. The trials will then evaluate and compare the effectiveness and tolerability of the 2 agents during 12 months of treatment in the post menopausal women with osteoporosis.


'"/>




Page: 1
Related medicine news :

1. First Vaccine Designed for Africa Cleared for Testing in Humans
2. Ajanta Launches Worlds First Once-A-Day Nimesulide Oral Formulation
3. First human clone is near
4. First Artificial Heart patient has Major setback
5. WHO Declares Vietnam First Country to Control SARS
6. Russia Reports First SARS Case
7. Hope for First New Melanoma Treatment in Decades
8. First global SARS meet opens
9. Stanford Medical Center Implements The First Virtual Cardiac Ultrasound
10. Hyderabad To Have Asia’s First Catheter Making Uni
11. First telesurgery